| Impact of a five-dimensional framework on R&D productivity at AstraZeneca P Morgan, DG Brown, S Lennard, MJ Anderton, JC Barrett, U Eriksson, ... Nature reviews Drug discovery 17 (3), 167-181, 2018 | 402 | 2018 |
| Good practices in model‐informed drug discovery and development: practice, application, and documentation EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ... CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016 | 274 | 2016 |
| Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment B Hamrén, E Björk, M Sunzel, MO Karlsson Clinical Pharmacology & Therapeutics 84 (2), 228-235, 2008 | 93 | 2008 |
| Longitudinal model‐based meta‐analysis in rheumatoid arthritis: an application toward model‐based drug development I Demin, B Hamrén, O Luttringer, G Pillai, T Jung Clinical Pharmacology & Therapeutics 92 (3), 352-359, 2012 | 57 | 2012 |
| A model for glucose, insulin, and beta‐cell dynamics in subjects with insulin resistance and patients with type 2 diabetes J Ribbing, B Hamrén, MK Svensson, MO Karlsson The Journal of Clinical Pharmacology 50 (8), 861-872, 2010 | 46 | 2010 |
| Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population … UG Eriksson, JW Mandema, MO Karlsson, L Frison, PO Gisleskog, ... Clinical pharmacokinetics 42, 687-701, 2003 | 45 | 2003 |
| Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection Y Aoki, D Röshammar, B Hamrén, AC Hooker Journal of pharmacokinetics and pharmacodynamics 44, 581-597, 2017 | 44 | 2017 |
| Modelling and simulation to improve decision‐making in clinical development CF Burman, B Hamrén, P Olsson Pharmaceutical Statistics 4 (1), 47-58, 2005 | 39 | 2005 |
| Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor α/γ agonist, after a single oral and intravenous dose in humans H Ericsson, B Hamren, S Bergstrand, M Elebring, L Fryklund, M Heijer, ... Drug metabolism and disposition 32 (9), 923-929, 2004 | 32 | 2004 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 31 | 2017 |
| Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus B Hamrén, KP Öhman, MK Svensson, MO Karlsson The Journal of Clinical Pharmacology 52 (9), 1317-1327, 2012 | 29 | 2012 |
| Comparison of the exposure–response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus J Parkinson, W Tang, CC Johansson, DW Boulton, B Hamrén Diabetes, Obesity and Metabolism 18 (7), 685-692, 2016 | 21 | 2016 |
| Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes E Nyman, YJW Rozendaal, G Helmlinger, B Hamrén, MC Kjellsson, ... Interface focus 6 (2), 20150075, 2016 | 21 | 2016 |
| Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function–evidence of interconversion B Hamrén, H Ericsson, O Samuelsson, MO Karlsson British journal of clinical pharmacology 65 (6), 855-863, 2008 | 19 | 2008 |
| Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term … S Bååthe, B Hamren, MO Karlsson, M Wollbratt, M Grind, UG Eriksson Clinical pharmacokinetics 45, 803-819, 2006 | 19 | 2006 |
| Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia [S] V Sokolov, G Helmlinger, C Nilsson, K Zhudenkov, S Skrtic, B Hamrén, ... Journal of Lipid Research 60 (9), 1610-1621, 2019 | 18 | 2019 |
| Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients M Åstrand, C Amilon, D Röshammar, A Himmelmann, DJ Angiolillo, ... British Journal of Clinical Pharmacology 85 (2), 413-421, 2019 | 17 | 2019 |
| Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction D Röshammar, M Bergstrand, T Andersson, RF Storey, B Hamrén International Journal of Clinical Pharmacology and Therapeutics 55 (5), 416, 2017 | 16 | 2017 |
| Population pharmacokinetics/pharmacodynamics of ticagrelor in children with sickle cell disease C Amilon, M Niazi, A Berggren, M Åstrand, B Hamrén Clinical Pharmacokinetics 58, 1295-1307, 2019 | 13 | 2019 |
| Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: A population analysis by … M Grind, B Hamren, S Baathe, M Wollbratt, UG Eriksson CLINICAL PHARMACOLOGY & THERAPEUTICS 71 (2), P31-P31, 2002 | 13 | 2002 |
